Ikena Oncology (NASDAQ:IKNA – Get Free Report) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their previous target price of $8.00. Wedbush’s […]